By Adriano Marchese

Aurora Cannabis said it expects revenue to fall in fiscal 2027 as the company pivots away from low-margin Canadian consumer operations and doubles down on its global medical cannabis business.

The Canadian medical cannabis producer said Thursday that it will shift its investments to Europe--particularly in Germany and Poland--and expand its European Union good manufacturing practice-certified production capacity, known as EU-GMP, to drive growth in its most profitable markets.

While the gains are expected to lift margins, Aurora said that total net revenue will decline next year, a drop compounded by cuts to government-reimbursed pricing in Canada that took effect in April.

"We are confident that these attributes create a competitive advantage as we navigate the evolving industry dynamics to maintain and expand global market share, while driving international growth," Chairman and Chief Executive Miguel Martin said.

The company said that for the three months ended March 31, total revenue rose over 10% to 84.8 million Canadian dollars ($60.8 million), topping expectations of a slight decline, according to FactSet.

Aurora said that growth over the prior year was mainly due to a 14% increase in the global medical cannabis business as well as higher wholesale bulk cannabis net revenue. Meanwhile, consumer cannabis was softer in the period, declining by more than half from the year-prior.

Net loss from continuing operations of C$27.6 million, compared with a loss of C$12.1 million. The quarter was weighed by other expenses amounting to C$1.7 million, compared to other income of C$11.9 million a year ago.

Stripping out exceptional items and one-off costs, adjusted earnings were C$5.6 million, down from C$15.3 million.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 11, 2026 08:19 ET (12:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.